Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal
- Determine the antitumor activity of temozolomide in adults with newly diagnosed
- Define the relationship between tumor O6-alkylguanine-DNA alkyltransferase activity and
tumor response in these patients.
- Define the relationship between tumor DNA mismatch repair activity and tumor response
OUTLINE: Patients receive temozolomide orally once daily on days 1-5. Treatment courses are
repeated every 28 days. In the absence of disease progression and toxicity, patients receive
up to 4 courses of treatment prior to radiation therapy. After radiation therapy, patients
demonstrating partial or complete response may receive an additional 12 courses of
Patients are followed every 8-12 weeks for 2 years.
PROJECTED ACCRUAL: This study will accrue 50 patients.
Primary Purpose: Treatment
Henry S. Friedman, MD
United States: Federal Government
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|